Delisted from NASDAQ in Mar 2023
QTNT - Quotient Limited
NASDAQ
->
Healthcare
->
Diagnostics & Research
Eysins,
Switzerland
Type: Equity
QTNT price evolution
QTNT
| (in millions $) | 31 Jan 2023 | 30 Sep 2022 | 30 Jun 2022 | 31 Mar 2022 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $25.35 | $54.88 | $73.8 | |
| Short term investments | $2.48 | $2.48 | $2.63 | |
| Net receivables | $6.27 | $5.18 | $5.06 | $6.27 |
| Inventory | $22.04 | $12.76 | $22.08 | $22.04 |
| Total current assets | $101.75 | $52.92 | $86.69 | $101.75 |
| Long term investments | $14.41 | $14.6 | $15.47 | |
| Property, plant & equipment | $62.65 | $55.19 | $59.61 | $62.65 |
| Goodwill & intangible assets | $0.41 | $0.47 | $0.52 | |
| Total noncurrent assets | $74.98 | $87.9 | $92.23 | |
| Total investments | $16.89 | $17.08 | $18.09 | |
| Total assets | $193.99 | $127.91 | $174.59 | $193.99 |
| Current liabilities | ||||
| Accounts payable | $4.52 | $3.75 | $5.5 | $4.52 |
| Deferred revenue | ||||
| Short long term debt | $4.03 | $4.09 | $4.07 | |
| Total current liabilities | $32.83 | $29.5 | $28.92 | $32.83 |
| Long term debt | $269.74 | $247.5 | $264.55 | $262.45 |
| Total noncurrent liabilities | $280.5 | $296.75 | $305.26 | |
| Total debt | $251.53 | $268.65 | $266.53 | |
| Total liabilities | $338.09 | $310 | $325.67 | $338.09 |
| Shareholders' equity | ||||
| Retained earnings | -$725.04 | -$809.84 | -$763.91 | -$725.04 |
| Other shareholder equity | -$6.19 | $21.04 | $6.16 | -$6.19 |
| Total shareholder equity | -$182.09 | -$151.08 | -$144.1 | |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $73.8 | $54.7 | $12.94 | $11.6 |
| Short term investments | $2.63 | $66 | $116.87 | $90.73 |
| Net receivables | $6.27 | $5.32 | $5.4 | $3.35 |
| Inventory | $22.04 | $22.01 | $20.5 | $15.55 |
| Total current assets | $101.75 | $143.88 | $150.47 | $116.93 |
| Long term investments | $15.47 | |||
| Property, plant & equipment | $62.65 | $60.54 | $61.66 | $47.29 |
| Goodwill & intangible assets | $0.52 | $0.62 | $0.63 | $0.75 |
| Total noncurrent assets | $92.23 | $75.39 | $75.99 | $60.84 |
| Total investments | $18.09 | $66 | $116.87 | $90.73 |
| Total assets | $193.99 | $219.27 | $226.46 | $177.77 |
| Current liabilities | ||||
| Accounts payable | $4.52 | $4.66 | $4.83 | $5.94 |
| Deferred revenue | $1.58 | |||
| Short long term debt | $4.07 | $28.45 | $3.63 | $0.47 |
| Total current liabilities | $32.83 | $58.83 | $31.16 | $25.45 |
| Long term debt | $262.45 | $159.29 | $174.06 | $122.72 |
| Total noncurrent liabilities | $305.26 | $189.48 | $200.83 | $150.61 |
| Total debt | $266.53 | $187.74 | $177.69 | $123.19 |
| Total liabilities | $338.09 | $248.31 | $231.99 | $176.06 |
| Shareholders' equity | ||||
| Retained earnings | -$725.04 | -$591.9 | -$483.44 | -$381.02 |
| Other shareholder equity | -$6.19 | -$16.07 | -$15.15 | -$14.88 |
| Total shareholder equity | -$144.1 | -$29.04 | -$5.53 | $1.71 |
| (in millions $) | 31 Jan 2023 | 30 Sep 2022 | 30 Jun 2022 | 31 Mar 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $8.86 | $8.81 | $9.79 | |
| Cost of revenue | $21.12 | $6.12 | $5.99 | |
| Gross Profit | -$12.26 | $2.69 | $3.8 | |
| Operating activities | ||||
| Research & development | $14.26 | $14.15 | $16.15 | |
| Selling, general & administrative | $11.21 | $14.34 | $14.52 | |
| Total operating expenses | $25.47 | $28.49 | $30.66 | |
| Operating income | -$37.73 | -$25.8 | -$26.86 | |
| Income from continuing operations | ||||
| EBIT | -$52.95 | -$30.16 | -$15.93 | |
| Income tax expense | $0.37 | $0.13 | -$0.06 | |
| Interest expense | -$7.39 | $8.57 | $10.04 | |
| Net income | ||||
| Net income | -$45.93 | -$38.87 | -$25.91 | |
| Income (for common shares) | -$45.93 | -$38.87 | -$25.91 | |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $38.51 | $43.38 | $32.66 | $29.13 |
| Cost of revenue | $23.57 | $20.07 | $17.8 | $17.23 |
| Gross Profit | $14.95 | $23.3 | $14.86 | $11.9 |
| Operating activities | ||||
| Research & development | $58.69 | $54.17 | $53.74 | $50.68 |
| Selling, general & administrative | $60.08 | $51.65 | $41.8 | $40.18 |
| Total operating expenses | $118.77 | $105.81 | $95.55 | $90.86 |
| Operating income | -$103.83 | -$82.51 | -$80.69 | -$78.95 |
| Income from continuing operations | ||||
| EBIT | -$92.22 | -$80.63 | -$78.25 | -$85.32 |
| Income tax expense | $0.96 | $1.93 | $0.66 | $0.04 |
| Interest expense | $31.95 | $25.92 | $23.86 | $20.02 |
| Net income | ||||
| Net income | -$125.13 | -$108.47 | -$102.77 | -$105.39 |
| Income (for common shares) | -$125.13 | -$108.47 | -$102.77 | -$105.39 |
| (in millions $) | 30 Sep 2022 | 30 Jun 2022 | 31 Mar 2022 | 31 Dec 2021 |
|---|---|---|---|---|
| Net income | -$45.93 | -$38.87 | -$25.91 | -$44.82 |
| Operating activities | ||||
| Depreciation | $1.45 | $1.46 | $1.72 | $1.85 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $0.04 | $1.63 | $1.42 | $1.51 |
| Total cash flows from operations | -$28.78 | -$35.52 | -$22.87 | -$37.48 |
| Investing activities | ||||
| Capital expenditures | -$0.27 | -$0.83 | -$0.57 | -$0.57 |
| Investments | $2.19 | |||
| Total cash flows from investing | -$0.27 | -$0.83 | -$0.57 | $1.63 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $17.9 | $0.01 | -$0 | |
| Net borrowings | -$0.16 | -$0.17 | -$0.18 | -$0.19 |
| Total cash flows from financing | -$0.16 | $17.74 | -$0.18 | -$0.19 |
| Effect of exchange rate | -$0.32 | -$0.31 | $4.05 | $0.13 |
| Change in cash and equivalents | -$29.53 | -$18.93 | -$19.57 | -$35.91 |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Net income | -$125.13 | -$108.47 | -$102.77 | -$105.39 |
| Operating activities | ||||
| Depreciation | $7.42 | $8.62 | $12.28 | $12.77 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $6.16 | $4.98 | $4.47 | $4.96 |
| Total cash flows from operations | -$119.04 | -$77.58 | -$80.65 | -$75.66 |
| Investing activities | ||||
| Capital expenditures | -$2.85 | -$4.24 | -$4.6 | -$4.79 |
| Investments | $46.92 | $47.69 | -$25.59 | -$84.27 |
| Total cash flows from investing | $44.07 | $43.45 | -$30.19 | -$89.06 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | -$0.08 | $80.88 | $90.97 | $115.02 |
| Net borrowings | $87.69 | -$0.63 | $23.6 | $30.4 |
| Total cash flows from financing | $87.62 | $80.25 | $114.58 | $145.42 |
| Effect of exchange rate | $6.46 | -$4.36 | -$2.4 | $5.69 |
| Change in cash and equivalents | $19.11 | $41.76 | $1.34 | -$13.6 |
News
|
Why Shares Of Chinese Companies Are Trading Lower? Here Are 54 Stocks Moving In Wednesday's Mid-Day...
Investing.com
29 Dec 2022
|
|
U.S. shares mixed at close of trade; Dow Jones Industrial Average up 0.11%
Investing.com
26 Dec 2022
|
|
Treace Medical Concepts (TMCI) Reports Q3 Loss, Tops Revenue Estimates
Zacks via Yahoo Finance
9 Nov 2022
|
|
Hologic (HOLX) Beats Q4 Earnings and Revenue Estimates
Zacks via Yahoo Finance
31 Oct 2022
|
|
Insiders who bought in the last 12 months lose an additional US$231k as Quotient Limited...
Simply Wall St. via Yahoo Finance
27 Sep 2022
|
|
Quotient (QTNT) Reports Q1 Loss, Lags Revenue Estimates
Zacks via Yahoo Finance
9 Aug 2022
|
|
Council Post: Enterprise Use Cases For Computer Vision
Forbes
29 Apr 2022
|
|
53 Biggest Movers From Yesterday
Benzinga
21 Apr 2022
|
|
No-Prep, No-Time, and Grudge Drag Racing Explained
MotorTrend
15 Apr 2022
|
|
$500/Month Passive TFSA Income: How to Achieve This
MSN News
30 Mar 2022
|
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 102.61M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | -2.35 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 3.10 |
| Quick ratio | 2.43 |